Polypills for cardiovascular prevention: A step forward?

Nature Reviews Cardiology

Volumn 10, Issue 12, 2013, Pages 683-684

  Sanz, Ginés ^a   Fuster, Valentin ^b  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; RAMIPRIL; SIMVASTATIN; VALSARTAN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG COMBINATION; FIXED DOSE COMBINATION; HUMAN; LIFESTYLE MODIFICATION; LOWEST INCOME GROUP; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; NOTE; STATISTICS;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PLATELET AGGREGATION INHIBITORS;

EID: 84888642132     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.157     Document Type: Article

References (10)

1. Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918-929 (2013).
2. Beaglehole, R. & Bonita, R. Global public health: a scorecard. Lancet 372, 1988-1996 (2008).
3. Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 378, 1231-1243 (2011).
4. Mendis, S. et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull. World Health Organ. 85, 279-288 (2007).
5. Chapman, R. H. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 165, 1147-1152 (2005).
6. Jansa, M. et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions: a cross-sectional study in a tertiary hospital. Patient Educ. Couns. 81, 161-168 (2010).
7. Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).
8. Elley, C. R. et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS ONE 7, e52145 (2012).
9. Sanz, G. & Fuster, V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J. Med. 79, 683-688 (2012).
10. Sanz, G. et al. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug: study design and objectives. Am. Heart J. 162, 811-817 (2011).